EUVIMEDOpdag EUVIMED
Crossref

Cip2a induces arginine biosynthesis and promotes tumor progression in non‐small cell lung cancer

Danyang Chen, Siwen Fan, Jun Wang, Yanqing Liang, Pan Li, Xinwu Lv, Yanqin Sun, Qian Wang, Hao Liu, Chuantao Zhang, Yanmei Yi iD

Molecular Carcinogenesis · 2023-04 · 62 (4) · 561-572

DOI: 10.1002/mc.23507 ↗

At a glance

Journal article in Molecular Carcinogenesis, published online on 2023-01-27. Written by Danyang Chen and 10 co-authors. Institution: Guangzhou Key Laboratory of "Translational Medicine on Malignant Tumor Treatment", Affiliated Cancer Hospital & Institute of Guangzhou Medical Univer…. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Cited 7 times so far (Crossref); 30 references. Funded by: General guidance project of Health Science and technology in Guangzhou, Medical Scientific Research Foundation of Guangdong, Guangdong Natural Science Funds.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cancerous inhibitor of protein phosphatase 2A (Cip2a) is an oncoprotein, playing important roles in tumor progression. However, the underlying mechanisms by which Cip2a promotes tumor aggressiveness in NSCLC remain to be further investigated. In this study, we found that Cip2a expression is elevated in NSCLC and correlates with poor prognosis. Knockdown of Cip2a significantly reduced the ability of cell proliferation, invasion, and metastasis of NSCLC both in vitro and in vivo. Furthermore, we found that Cip2a promotes tumor progression partly by inducing arginine biosynthesis, and knockdown of Cip2a exhibited a significantly increased sensitivity to arginine deprivation and mTOR inhibition. In addition, we found that p53 mutants in NSCLC cells increased Cip2a expression by inhibiting the activity of wild‐type p53. Our findings provide new insights into the mechanisms of Cip2a in promoting tumor progression and suggest that Cip2a represents a potential therapeutic target for treating NSCLC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansTumor Suppressor Protein p53Cell ProliferationAutoantigensCell Line, Tumor

Author keywords

Cip2aNSCLCarginine biosynthesis

Substances

Tumor Suppressor Protein p53Autoantigens

Authors and institutions

  • Guangzhou Key Laboratory of "Translational Medicine on Malignant Tumor Treatment", Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong, China.
  • Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

ORCID profiles: Yanmei Yi

Funding

  • General guidance project of Health Science and technology in Guangzhou
  • Medical Scientific Research Foundation of Guangdong
  • Guangdong Natural Science Funds
  • National Natural Science Foundation of China

Cite

APA

Chen, D., Fan, S., Wang, J., Liang, Y., Li, P., Lv, X., Sun, Y., Wang, Q., Liu, H., Zhang, C., & Yi, Y. (2023). Cip2a induces arginine biosynthesis and promotes tumor progression in non‐small cell lung cancer. Molecular Carcinogenesis, 62(4), 561-572. https://doi.org/10.1002/mc.23507

Vancouver

Chen D, Fan S, Wang J, Liang Y, Li P, Lv X, et al. Cip2a induces arginine biosynthesis and promotes tumor progression in non‐small cell lung cancer. Molecular Carcinogenesis. 2023;62(4):561-572. doi:10.1002/mc.23507

BibTeX
@article{Chen2023,
  author = {Chen, Danyang and Fan, Siwen and Wang, Jun and Liang, Yanqing and Li, Pan and Lv, Xinwu and Sun, Yanqin and Wang, Qian and Liu, Hao and Zhang, Chuantao and Yi, Yanmei},
  title = {Cip2a induces arginine biosynthesis and promotes tumor progression in non‐small cell lung cancer},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  volume = {62},
  number = {4},
  pages = {561--572},
  doi = {10.1002/mc.23507}
}
Start for free →